Journal: bioRxiv

Article Title: Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics

doi: 10.1101/2021.07.21.453274

Figure Lengend Snippet: Structures of the prodrugs Sofosbuvir (a), Remdesivir (b), Favipiravir (c), Tenofovir disoproxil (d), Molnupiravir (e) and AT-527 (f) (top) and their respective active triphosphate forms Sofosbuvir-5’-triphosphate, Remdesivir-5’-triphosphate, Favipiravir-ribofuranosyl-5’-triphosphate (Favipiravir-RTP), Tenofovir diphosphate, N 4 -hydroxycytidine-5’-triphosphate (NHC-TP) and 2’-fluoro-2’-methyl guanosine-5’-triphosphate (AT-9010, G fm -TP) (bottom).

Article Snippet: Remdesivir triphosphate (RDV-TP) and NHC triphosphate were purchased from MedChemExpress (Monmouth Junction, NJ), Sofosbuvir triphosphate (SOF-TP) was purchased from Sierra Bioresearch (Tucson, AZ), Tenofovir diphosphate (Tfv-DP) was purchased from Alfa Chemistry (Ronkonkoma, NY), and Favipiravir triphosphate and AT-9010 were purchased from NuBlocks LLC (Oceanside, CA).

Techniques:

Journal: Clinical and Translational Science

Article Title: A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19

doi: 10.1111/cts.13395

Figure Lengend Snippet: Summary statistics for pharmacokinetics of NHC in plasma and NHC‐TP in PBMC following single oral dose administration of molnupiravir in healthy Japanese male participants, part 1

Article Snippet: Plasma NHC and PBMC NHC‐TP assays were performed by Labcorp Early Development Laboratories and Clinical Pharmacology Analytical Laboratory at The Johns Hopkins University School of Medicine, respectively.

Techniques: Drug discovery, Clinical Proteomics

Journal: Clinical and Translational Science

Article Title: A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19

doi: 10.1111/cts.13395

Figure Lengend Snippet: Mean PBMC concentration‐time profiles for NHC‐TP following single oral dose administration of molnupiravir (fasted state) to healthy Japanese male participants (part 1). Arithmetic mean + SD. Top: Linear plot, bottom: semi‐log plot; n = 6 beyond 8 h at 800 mg. NHC‐TP, N ‐hydroxycytidine triphosphate; PBMC, peripheral blood mononuclear cell.

Article Snippet: Plasma NHC and PBMC NHC‐TP assays were performed by Labcorp Early Development Laboratories and Clinical Pharmacology Analytical Laboratory at The Johns Hopkins University School of Medicine, respectively.

Techniques: Concentration Assay

Journal: Clinical and Translational Science

Article Title: A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19

doi: 10.1111/cts.13395

Figure Lengend Snippet: Summary statistics for pharmacokinetics of NHC in Plasma and NHC‐TP in PBMC following multiple oral dose administration of molnupiravir q12h for 5.5 days in healthy Japanese male participants, part 2

Article Snippet: Plasma NHC and PBMC NHC‐TP assays were performed by Labcorp Early Development Laboratories and Clinical Pharmacology Analytical Laboratory at The Johns Hopkins University School of Medicine, respectively.

Techniques: Drug discovery, Clinical Proteomics